论文部分内容阅读
Purpose:Diabetic macular edema (DME) is a trequent manifestation of diabetic retinopathy which is the most common microvascular complications of diabetes mellitus, accounting for 13％ visual impairment in patients with diabetes.Ranibizumab (solution for injection) is the only recombinant humanized immunoglobulin G 1 kappa isotype monoclonal antibody fragment targeted against human vascular endothelial growth factor A (VEGF-A) which is approved by FDA, EMA and many other countries for treatment of visual impairment due to DME.A pharmacokinetic (PK) and population PK (PPK) analysis was conducted in Chinese DME patients to characterize the PK of ranimizumab in the serum after intravitreal injection of Chinese patients with visual impairment due to DME.